

REMARKS/ARGUMENTS

Restriction to one of the following inventions is required under 35 U.S.C. §121:

- I. Claims 1-8, drawn to an isolated nucleic acid, a vector, a host cell, and a process of producing a PRO polypeptide.
- II. Claims 9, 14-17 (in part), drawn proteins
- III. Claims 14-17 (in part), drawn to an antibody.
- IV. Claims 14-17 (in part), drawn to agonist molecules or compositions. .
- V. Claims 14-17 (in part), drawn to antagonist molecules or compositions
- VI. Claims 18 and 19 (in part), drawn to a method of treating a B-cell related disorder with a protein.
- VII. Claims 18 and 19 (in part), drawn to a method of treating a B-cell related disorder with an agonist.
- VIII. Claims 18 and 19 (in part), drawn to a method of treating a B-cell related disorder with an antagonist.
- IX. Claims 18 and 19 (in part), drawn to a method of treating a B-cell related disorder with an antibody.
- X. Claim 20, drawn to assay for PRO protein using antibodies.
- XI. Claims 21, 22 and 28, drawn to a method of diagnosing a B-cell related disorder using antibodies.
- XII. Claims 23-25, drawn to an assay for an antagonist using cells.
- XIII. Claim 26, drawn to an assay for an agonist using cells.
- XIV. Claim 27, drawn to a method of stimulating a B cell response using an antagonist.

Applicants elect Groups III with traverse, Claims 14-17 (in part), drawn to an antibody which specifically binds to a polypeptide according to claim 10 and composition thereof.

Applicants further elect SEQ ID NO:171 (nucleic acid) and 172 (polypeptide) (PRO4767;DNA103440) for further prosecution.

Applicants have canceled Claims 1-11 and 18-28, which are directed to non-elected subject matter. Claim 12 have been amended to delete the non-elected SEQ ID NOS. The amendments are fully supported by the specification and claims originally filed and do not


introduce any new matter. Applicants reserve the right to pursue the canceled subject matters in a continuation, continuation-in-part, or a divisional application. Claims 12-17 are pending after the amendment. Applicants respectfully request that the Examiner consider the amendment.

CONCLUSION

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned attorney at the telephone number shown below. Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 07-1700 (referencing Attorney's Docket No. GNE-0273 R1).

Respectfully submitted,

Dated: July 3, 2008

By: 
Panpan Gao (Reg. No. 43,626)

GOODWIN PROCTER LLP
135 Commonwealth Drive
Menlo Park, California 94025
Telephone: (650) 752-3100
Facsimile: (650) 853-1038